Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)

Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)
Department of Health and Human Services
National Institutes of HealthCounterACT

This FOA will only support translational research. Translational research is the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease. Projects supported by this FOA are expected to generate at least one lead compound by the end of the project period.  Compounds that may become leads could be from a variety of sources including high-throughput screens, drug discovery databases, and FDA-approved drugs that may be re-purposed.  For the purpose of this FOA, lead compounds are defined as biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds resulting from research supported by this FOA must have sufficiently strong preliminary preclinical safety/toxicity and in vivo efficacy data to support and promote a promising pathway toward more advanced development (not supported by this FOA) leading to the pre-IND stage.  The research supported by this FOA is intended generate lead compounds that are excellent candidates for optimization. Possible support for these advanced drug development activities could be obtained through other avenues such as the program described in the companion FOA “CounterACT Optimization of Therapeutic Lead Compounds (U01)” (PAR-16-128), as well as other government, commercial, or non-profit sources.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-129
Funding Opportunity Title: Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Environment
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.113 — Environmental Health
93.846 — Arthritis, Musculoskeletal and Skin Diseases Research
93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
93.867 — Vision Research
Cost Sharing or Matching Requirement: No
Posted Date: Mar 10, 2016
Last Updated Date: Mar 10, 2016
Original Closing Date for Applications: Sep 11, 2018  
Current Closing Date for Applications: Sep 11, 2018  
Archive Date: Oct 12, 2018
Estimated Total Program Funding:
Award Ceiling: $300,000
Award Floor:

Eligibility

Eligible Applicants:
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Native American tribal governments (Federally recognized)
County governments
Public and State controlled institutions of higher education
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests new research applications for Cooperative Agreement Research Projects (U01s) seeking support for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies must result in the identification of at least one lead compound ready for advanced therapeutic development. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA “CounterACT Optimization of Therapeutic Lead Compound (U01)” (PAR-16-XXX). The scope of this FOA encompasses Technical Readiness Level (TRL) 3 – see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-129.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s